心脏缩的新型模型与心脏脏功能障碍
Amanda de Almeida Silva1,2, Leonardo Jensen3, Juliana Romeu Marques3
1Experimental Pathophysiology Program, University of São Paulo Medical School, São Paulo, Brazil. manda.a.silva94@gmail.com.
Scientific reports
|July 19, 2025
概括
这项研究引入了一种新的小鼠模型,用于研究心脏缩和心脏脏功能障碍. 通过将横向大动脉收缩 (TAC) 与氧化酸盐 (OXA) 进行测量,有效地模拟了晚期心血管和脏疾病.
科学领域:
- 心血管研究研究心血管研究
- 腎臟病學 (nephrology) 是一種醫學專業.
- 实验病理学实验病理学
背景情况:
- 心血管疾病 (CVD) 是一个主要的全球健康问题,高血压 (HTN) 是一个关键的危险因素.
- HTN有助于心脏缩和功能障碍,需要更好的实验模型.
- 了解HTN,心脏缩和功能障碍之间的相互作用对于开发有效的治疗方法至关重要.
研究的目的:
- 为了研究一种结合横向大动脉收缩 (TAC) 和氧酸盐 (OXA) 的新型实验模型的疗效.
- 评估这种组合模型是否可以诱导心脏缩与心脏脏功能障碍.
- 为了比较组合模型与单独TAC或OXA测量结果的效果.
主要方法:
- 使用了四组C57BL/6小鼠:SHAM,TAC,OXA,以及TAC+OXA.
- TAC涉及到大动脉收缩手术,而OXA涉及到胃口的管理.
- 在8周后,评估了生理参数,心脏结构,自主调节,基因表达 (SERCA2) 和功能.
主要成果:
- 单独TAC就会导致心脏缩和脏炎症,但不会导致功能障碍.
- OXA测量增加了自主调节,并诱导损伤,但没有心脏变化.
- 综合TAC+OXA模型显著增加血压,诱导心脏缩,肺堵塞,降低巴罗反射灵敏度,并导致功能障碍.
结论:
- TAC和OXA测量组合创建了一个新的和有效的模型来研究心脏缩与心脏脏功能障碍.
- 与单个干预相比,这种综合模型显示出更高程度的心脏失补偿和显著的功能障碍.
- 这种模型为阐明心综合征背后的机制提供了有价值的工具.
相关概念视频
01:29Heart Failure II: Pathophysiology
45
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
45
01:17Pathophysiology of Heart Failure
1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
01:29Hypertension II: Pathophysiology
85
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
85
01:22Heart Failure Drugs: Diuretics
495
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
495
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
52
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
52